NASDAQ · LEXX
Lexaria Biosciences
Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and many more patents pending worldwide. Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery.
Increases bio-absorption many-fold
Reduces time of onsest from 1-2 hours to minutes
Delivers drugs more effectively across the blood brain barrier
Improves tolerability
Increases bio-absorption many-fold
Reduces time of onsest from 1-2 hours to minutes
Delivers drugs more effectively across the blood brain barrier
Improves tolerability
Increases bio-absorption many-fold
Reduces time of onsest from 1-2 hours to minutes
Delivers drugs more effectively across the blood brain barrier
Improves tolerability
Increases bio-absorption many-fold
Reduces time of onsest from 1-2 hours to minutes
Delivers drugs more effectively across the blood brain barrier
Improves tolerability
Join to participate in polls
Members can vote on shareholder polls and see results.